---
title: "Guanhao Biotech released its performance for the first three quarters, with a net profit attributable to the parent company of 26.7185 million yuan, a decrease of 4.02%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/263051463.md"
description: "Guanhao Biotech released its Q3 2025 report, with a revenue of 293 million yuan for the first three quarters, a year-on-year increase of 5.52%. The net profit attributable to the parent company was 26.7185 million yuan, a year-on-year decrease of 4.02%; the net profit excluding non-recurring gains and losses was 25.8206 million yuan, a year-on-year increase of 27.60%. The basic earnings per share were 0.1 yuan"
datetime: "2025-10-28T09:54:04.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/263051463.md)
  - [en](https://longbridge.com/en/news/263051463.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/263051463.md)
---

# Guanhao Biotech released its performance for the first three quarters, with a net profit attributable to the parent company of 26.7185 million yuan, a decrease of 4.02%

According to the Zhitong Finance APP, Guanhao Biotech (300238.SZ) released its third-quarter report for 2025. The company's operating revenue for the first three quarters was 293 million yuan, a year-on-year increase of 5.52%. The net profit attributable to shareholders of the listed company was 26.7185 million yuan, a year-on-year decrease of 4.02%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 25.8206 million yuan, a year-on-year increase of 27.60%. The basic earnings per share were 0.1 yuan

### Related Stocks

- [300238.CN](https://longbridge.com/en/quote/300238.CN.md)

## Related News & Research

- [Global Inflation Fears Are Driving Bond Yields Higher. Make This 1 Trade Now.](https://longbridge.com/en/news/286932294.md)
- [What happens if you only invest in index funds for 30 years?](https://longbridge.com/en/news/286940398.md)
- [Rising Bond Yields Weigh on Stocks](https://longbridge.com/en/news/286939009.md)
- [Phase 3-ready cancer biotech Parabilis Medicines files for a $100 million IPO](https://longbridge.com/en/news/286972125.md)
- [Motiva Port Arthur refinery reports crude oil release after pipe issues](https://longbridge.com/en/news/286971029.md)